Wells Fargo raised the firm’s price target on AnaptysBio (ANAB) to $51 from $40 and keeps an Overweight rating on the shares. The firm believes ...

Wedbush analyst David Nierengarten maintained a Buy rating on AnaptysBio (ANAB – Research Report) today and set a price target of $40.00. The company’s shares closed yesterday at $16.08.

Shares of ANAB stock opened at $16.06 on Tuesday. The firm has a market cap of $488.71 million and a P/E ratio of -2.64. The firm’s 50 day moving average price is $17.05 and its 200-day moving ...

AnaptysBio (NASDAQ:ANAB – Get Free Report)‘s stock had its “outperform” rating reaffirmed by equities researchers at Wedbush in a research note issued to investors on Monday,RTT News reports.

OpenAI’s big rebranding effort brings a new logo and a new typeface, OpenAI sans. OpenAI’s big rebranding effort brings a new logo and a new typeface, OpenAI sans. Emma Roth is a news writer ...

(Anaptys) (Nasdaq: ANAB) today announced an exclusive ... in patients with Generalized Pustular Psoriasis (GPP). Vanda Logo (PRNewsfoto/Vanda Pharmaceuticals Inc.) GPP is a rare skin disorder ...

The firm increased its portfolio allocation in ANAB by 55.02% over the last quarter. Frazier Life Sciences Management holds 2,209K shares representing 7.26% ownership of the company. In its prior ...